Recent development of gastric cancer prevention

Japanese Journal of Clinical Oncology

Volumn 42, Issue 11, 2012, Pages 987-994

  Kato, Mototsugu ^a   Asaka, Masahiro ^b  

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Endoscopy; H. pylori eradication; Pepsinogen; Photofluorography; Screening

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFECTIVE AGENT; CAROTENOID; PEPSINOGEN;

ATROPHIC GASTRITIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COHORT ANALYSIS; DIET THERAPY; DISEASE CONTROL; ENDOSCOPIC SURGERY; FLUOROGRAPHY; HELICOBACTER INFECTION; HUMAN; MASS SCREENING; NONHUMAN; NUTRITION; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; STOMACH CARCINOGENESIS; STRATIFIED SAMPLE;

ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MASS SCREENING; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84868138497     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys151     Document Type: Review

References (66)

1. Kakizoe T. Chemoprevention of cancer-focusing on clinical trials. Jpn J Clin Oncol 2003;33:421-42.
2. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J 2005;81:419-24.
3. Hisamichi S, Sugawara N. Mass screening for gastric cancer by X-ray examination. Jpn J Clin Oncol 1984;11:211-33.
4. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-7.
5. Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 2007;10:75-83.
6. Wiseman M. The Second World Cancer Research Fund/American Institute for Cancer Research Expert Report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 2008;67:253-6.
7. Palli D. Epidemiology of gastric cancer. Ann Ist Super Sanita 1996;32:85-99.
8. Kato S, Tsukamoto T, Mizoshita T, et al. High salt diets dose-dependently promote gastric chemical carcinogenesis in Helicobacter pylori-infected Mongolian gerbils associated with a shift in mucin production from glandular to surface mucous cells. Int J Cancer 2006;119:1558-66.
9. Kobayashi M, Tsubono Y, Sasazuki S, Sasaki S, Tsugane S., JPHC Study Group. Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC Study Cohort I. Int J Cancer 2002;102:39-44.
10. Lunet N, Lacerda-Vieira A, Barros H. Fruit and vegetables consumption and gastric cancer: a systematic review and meta-analysis of cohort studies. Nutr Cancer 2005;53:1-10.
11. Poydock ME, Fardon JC, Gallina D, Ferro V, Heher C. Inhibiting effect of vitamins C and B12 on the mitotic activity of ascites tumors. Exp Cell Biol 1979;47:210-7.
12. Palace VP, Khaper N, Qin Q, Singal PK. Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. Free Radic Biol Med 1999;26:746-61.
13. Rousseau EJ, Davison AJ, Dunn B. Protection by beta-carotene and related compounds against oxygen-mediated cytotoxicity and genotoxicity: implications for carcinogenesis and anticarcinogenesis. Free Radic Biol Med 1992;13:407-33.
14. Wang ZY, Cheng SJ, Zhou ZC, Athar M, Khan WA, Bickers DR. Antimutagenic activity of green tea polyphenols. Mutat Res 1989;223:273-85.
15. Xu Y, Ho CT, Amin SG, Han C, Chung FL. Inhibition of tobacco specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenols as antioxidants. Cancer Res 1992;52:3875-9.
16. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009;100:551-7.
17. Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 2010;28:2952-7.
18. Yanaoka K, Oka M, Yoshimura N, et al. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int J Cancer 2010;126:1467-73.
19. Kato M, Asaka M. Recent knowledge of the relationship between Helicobacter pylori and gastric cancer and recent progress of gastroendoscopic diagnosis and treatment for gastric cancer. Jpn J Clin Oncol 2010;40:828-37.
20. Shimizu N, Ikehara Y, Inada K, et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 2000;60:1512-4.
21. Nozaki K, Shimizu N, Ikehara Y, et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci 2003;94:235-9.
22. Take S, Mizuno M, Ishiki K. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol 2007;42(Suppl 17):21-7.
23. Takenaka R, Okada H, Kato J, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther 2007;25:805-12.
24. Ogura K, Hirata Y, Yanai A, et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol 2008;42:279-83.
25. Yanaoka K, Oka M, Ohata H, Yanaoka K, Oka M, Ohata H. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer 2009;125:2697-703.
26. Mabe K, Takahashi M, Oizumi H, et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? World J Gastroenterol 2009;15:4290-7.
27. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009;137:1641-8.
28. Wong BC, Lam SK, Wong WM, et al. China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.
29. Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151:121-8.
30. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8.
31. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-83.
32. Saito D, Boku N, Fujioka T, Fukuda Y. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial [Abstract]. Gastroenterology 2005;128:A4.
33. Zhou L. Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China [Abstract]. Gastroenterology 2008;134:A233.
34. Ford AC, Moayyedi P. Redundant data in the meta-analysis on Helicobacter pylori eradication. Ann Intern Med 2009;151:513; author reply 513-4.
35. Maehata Y, Nakamura S, Fujisawa K, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 2012;75:39-46.
36. Kato M, Asaka M, Ono S, et al. Eradication of Helicobacter pylori for Primary Gastric Cancer and Secondary Gastric Cancer after EMR. J Gastroenterol 2007;42(Suppl 17):16-20.
37. Asaka M, Kato M, Graham DY. Prevention of gastric cancer by Helicobacter pylori eradication. Intern Med 2010;49:633-6.
38. Isobe Y, Nashimoto A, Akazawa K, et al. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer 2011;14:301-16.
39. Hamashima C, Saito H, Nakayama T, Nakayama T, Sobue T. The standardized development method of the Japanese guidelines for cancer screening. Jpn J Clin Oncol 2008;38:288-95.
40. Hamashima C, Shibuya D, Yamazaki H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008;38:259-67.
41. Asaka M, Kato M, Graham DY. Strategy for eliminating gastric cancer in Japan. Helicobacter 2010;15:486-90.
42. Asaka M, Kato M, Takahashi S, et al. Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15:1-20.
43. Nakajima S, Nishiyama Y, Yamaoka M, Yasuoka T, Cho E. Changes in the prevalence of Helicobacter pylori infection and gastrointestinal diseases in the past 17 years. J Gastroenterol Hepatol 2010;25:S99- S110.
44. Hayashi Y, Yamamoto Y, Suganuma T, et al. Comparison of the diagnostic utility of the ultrathin endoscope and the conventional endoscope in early gastric cancer screening. Dig Endosc 2009;21:116-21.
45. Yagi J, Adachi K, Arima N, et al. A prospective randomized comparative study on the safety and tolerability of transnasal esophagogastroduodenoscopy. Endoscopy 2005;37:1226-31.
46. Murata A, Akahoshi K, Sumida Y, Yamamoto H, Nakamura K, Nawata H. Prospective randomized trial of transnasal versus peroral endoscopy using an ultrathin videoendoscope in unsedated patients. J Gastroenterol Hepatol 2007;22:482-5.
47. Tashiro A, Sano M, Kinameri K, Fujita K, Takeuchi Y. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol 2006;12:4873-4.
48. Matsumoto S, Yamasaki K, Tsuji K, Shirahama S. Results of mass endoscopic examination for gastric cancer in Kamigoto Hospital, Nagasaki Prefecture. World J Gastroenterol 2007;13:4316-20.
49. Samloff IM. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 1971;61:185-8.
50. Samloff IM, Liebman WM. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 1973;65:36-42.
51. Sipponen P, Samloff IM, Saukkonen M, Varis K. Serum pepsinogens I and II and gastric mucosal histology after partial gastrectomy. Gut 1985;26:1179-82.
52. Samloff IM, Stemmermann GN, Heilbrum LK, Nomura A. Elevated serum pepsinogen I and II levels differ as risk factors for duodenal ulcer and gastric ulcer. Gastroenterology 1986;90:570-6.
53. Miki K, Ichinose M, Shimizu A, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroentrol Jpn 1987;22:133-41.
54. Borch K, Axelsson CK, Halgreen H, Damkjaer N, Ledin T, Szesci PB. The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. Scand J Gastroenterol 1989;24:870-6.
55. Asaka M, Kato M, Kudo M, et al. Relationship between Helicobacter pylori infection, atrophic gastritis and gastric carcinoma in a Japanese population. Eur J Gastroenterol Hepatol 1995;7(Suppl 1):S7-10.
56. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005;54:764-8.
57. Oishi Y, Kiyohara Y, Kubo M, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006;163:629-37.
58. Yanaoka K, Oka M, Mukoubayashi C, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008;17:838-45.
59. Yoshihara M, Hiyama T, Yoshida S, et al. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study. Scand J Gastroenterol 2007;42:760-4.
60. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-43.
61. Mizuno S, Miki I, Ishida T, et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci 2010;55:3132-7.
62. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels- 'ABC method'. Proc Jpn Acad Ser B Phys Biol Sci 2011;87:405-14.
63. Fock KM, Talley N, Moayyedi P, et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008;23:351-65.
64. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-600.
65. Koinuma N, Ogata T, Misawa J. Pharmacoeconomic assessment of gastric cancer treatment (In Japanese). Nippon Rinsho 2008;66:639-52.
66. Asaka M. Extermination of gastric cancer from Japan (In Japanese). Nippon Shokakibyo Gakkai Zasshi 2010;107:359-64.